Director, Consumer Marketing - LYBALVI Brand Team

The Director will be responsible for the strategy and execution of LYBALVI Consumer Marketing activities supporting the bipolar 1 disorder and schizophrenia indications of LYBALVI. This includes Direct-to-Consumer (DTC) strategy, media plan, content development, and analysis. The position requires an experienced and highly motivated individual with strong strategic and leadership capabilities.

Alkermes has recently adopted a hybrid working environment to support and meet the needs of employees and this role will operate in a flexible environment with 60% of time in the office and 40% from home.

Responsibilities

Job Responsibilities Include :

• Leads development of the strategy, planning, and execution of Consumer Marketing, including annual brand planning
• Leads development of the strategy, content, media plan, analysis and optimization for the DTC campaign
• Leads Consumer marketing team (2) providing direction, coaching, and development of staff
• Understands the trends in bipolar 1 disorder and schizophrenia, drivers of consumer behavior, and how to reach and engage Serious Mental Illness (SMI) patients
• Directs and manages agency partners through the development of branded online and offline material including TV, digital and print advertising collateral
• Directs and manages media agency to ensure optimal placement of DTC assets
• Directs and manages the Consumer marketing budget, including Statement of Work (SOW) and change orders, accruals, and budget forecasting
• Works with cross functional team to forecast, analyze, and optimize DTC spend
• Provides input and direction to market research while guiding application of insights from Consumer research studies

Qualifications

Minimum Education & Experience Requirements :

Preferred Skill and Knowledge Qualifications :

LI-tt1 #LI-hybrid

About Us

Why join Team Alkermes?

Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, headquartered in Ireland with U.S. locations in Massachusetts and Ohio, we are committed to pursuing great science, driven by deep compassion to make a real impact in the lives of patients. Alkermes has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for various neurological disorders, including narcolepsy.

Beyond our important mission of developing medicines to address unmet patient needs, we actively seek to foster a culture of diversity, inclusion and belonging throughout our business. We strive to ensure that all voices are respected and valued, recognizing that our diversity of thought, background and perspective makes us stronger. We are proud to have been recognized as an employer of choice by many national organizations, including being certified as a Great Place to Work in the U.S. in 2024, honored as a Healthiest Employer in both Ohio and Massachusetts in 2023, a Best Place for Working Parents in 2023, and to have received the Bell Seal at the Platinum level for Workplace Mental Health by Mental Health America for three consecutive years (2021-2023).

Alkermes, Inc. is an equal employment opportunity employer and does not discriminate against any qualified applicant or employee because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender expression and identity, disability, genetic information, veteran status, military status, application for military service or any other characteristic protected by local, state or federal law. Alkermes also complies with all work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Alkermes is an E-Verify employer.

PDN-9df080a1-c825-40e9-93fb-316dcf2e3210